

The Neuro4D Conference 2024

Atrium Hotel Mainz – Mainz, Germany – Close to Frankfurt Airport



DEGENERATIVE
DISEASE
DRUG
DISCOVERY

**MONDAY
MAY 27TH**

8:00		
Registration and Joint Breakfast, attach Posters		
8:30		
Opening of the Conference: Andreas Köpke, bioExert		
9:00		
Common proteopathic neurodegenerative disease mechanisms <i>Chair: Janine Kutzsche , Research Center Jülich, Germany</i>		
PANEL 09:30 – 10:30		
ALS Disease Mechanism	How TDP43 reactivates endogenous retroviruses	Roger Sher Stony Brook University, USA
Enabling Technology	Longitudinal characterization of a transgenic B6.SOD1-G93A mutant based ALS mouse model	Roland Rabl Scantox, Austria
ALS Disease Mechanism	Post-translational modifications driving TDP-43 phase separation and aggregation	Philipp Kahle U. Tübingen, Germany
Panel Q&A of Session Speakers <i>Chair: Janine Kutzsche , Research Center Jülich, Germany</i>		
10:30 – 11:30		
Coffee Break, Exhibition & Poster Viewing		
PANEL 11:30 – 12:30		
PD Disease Mechanism	A common gene expression signature in α -synuclein-based and other mouse models of Parkinson's disease	Manuel Buttini U. Luxembourg
Enabling Technology	Use of PFF and similar models of Parkinson's disease in preclinical drug testing	Daniel Havas Psychogenics, USA
PD Disease Mechanism	Classifying Parkinson's disease through biology	Tiago Outeiro U. Göttingen, Germany
Panel Q&A of Session Speakers <i>Chair: Janine Kutzsche , Research Center Jülich, Germany</i>		
12:30		
Lunch		

The Neuro4D Conference 2024

Atrium Hotel Mainz – Mainz, Germany – Close to Frankfurt Airport



**MONDAY
MAY 27TH**

13:30		
New Therapeutic Options for Proteopathic Diseases	ALS, FTLN, AD, and LATE, different diseases with similar treatment options?	Neil Cashman ProMIS, Canada
PANEL 14:00 – 15:00		
AD New Treatment Strategies	Targeting tau oligomerization as a therapeutic approach for AD and other tauopathies	Joseph Rayman Columbia University, USA
Enabling Technology	Assessment of functional deficits in preclinical animal studies	Joseph Araujo Intervivo Solutions, Canada
AD New Treatment Strategies	Nasal immunotherapy effectively clears intracellular tau pathology via TRIM21 and improves cognitive functions in a tauopathy mouse model	Rakez Kaye UTMB, USA
Panel Q&A of Session Speakers <i>Chair: Neil Cashman, ProMIS, Canada</i>		
15:00 – 17:00		
Coffee Break, Exhibition & Poster Session (All Presenters will be at their posters for discussion. Please vote for the best poster!) One on One Meetings		
PANEL 17:00 – 18:00		
AD New Treatment Strategies	Identification of deubiquitinating enzymes (DUBs) regulating seeded tau pathology: new therapeutic strategies for tauopathies?	Christiane Volbracht H. Lundbeck, Denmark
PD New Treatment Strategies	Structure-based vaccine candidates for Parkinson's disease	Erdem Gültekin Tamgüney Research Center Jülich, Germany
AD Drug Discovery	Characterization of amyloid- β species in AD brain and the unique binding properties of Lecanemab	Linda Söderberg Bioartec, Schweden
Panel Q&A of Session Speakers <i>Chair: Neil Cashman, ProMIS, Canada</i>		
18:00		
Champagne Reception in the Foyer		
19:00 – 22:00		
Dinner We will have a seated dinner, accompanied by fitting local wines. Depending on the weather, we will be on the hotel terrace, or in an adjacent room. There will be music by Julio Hierrezuelo and band again!		
END OF THE FIRST DAY		

The Neuro4D Conference 2024

Atrium Hotel Mainz – Mainz, Germany – Close to Frankfurt Airport



DEGENERATIVE
DISEASE
DRUG
DISCOVERY

**TUESDAY
MAY 28TH**

7:30		
Joint Breakfast, Exhibition & Poster Viewing (Please vote for the best poster!)		
8:30		
AD New Treatment Strategies	Towards harnessing innate immunity targets to treat Alzheimer's disease	Michael Heneka U. Luxembourg
PANEL 9:00 – 10:00		
HD Disease Mechanism	Uncovering neurotoxic mechanisms of self-propagating huntingtin aggregates in Drosophila	Erich Wanker Max-Delbrück-Center, Berlin, Germany
HD New Treatment Strategy	Selective protein lowering strategies in Huntington's disease	Eric Reits U. Amsterdam, The Netherlands
PD-Clinical Results	The clinical failure of venglustat: should we now avoid targeting lysosomal pathways?	Franziska Richter Assencio U. of Veterinary Medicine Hannover, Germany
Panel Q&A of Session Speakers Chair: Michael Heneka, U. Luxembourg		
10:00 – 11:00		
Coffee Break, Exhibition and Posters: Presenters are at the Poster to discuss (Final chance to rate the best poster!) Time for One on One Meetings		
PANEL 11:00 – 12:00		
Enabling Technology	Quantification of α -Syn oligomers in body liquids	Oliver Bannach Attyloid, Germany
AD Biomarker	CSF A β oligomers peak in early clinical stages of Alzheimer's disease and precede tau pathology	Dieter Wilbold Heinrich-Heine-University, Germany
AD – Implications for Transfer of Clinical Material	Iatrogenic Alzheimer's disease in recipients of cadaveric pituitary-derived growth hormone	Tzehow Mok MRC Prion Unit, London, UK
Panel Q&A of Session Speakers Chair: Michael Heneka, U. Luxembourg		
12:00		
Lunch		

The Neuro4D Conference 2024

Atrium Hotel Mainz – Mainz, Germany – Close to Frankfurt Airport



DEGENERATIVE
DISEASE
DRUG
DISCOVERY

**TUESDAY
MAY 28TH**

13:00		
Clinical Studies in Neurodegenerative Diseases	Biomarker-based disease modification in preclinical stages of Alzheimer's disease	Oliver Peters Psychiatric Clinic Frankfurt Oder, Germany
PANEL 13:30 – 14:30		
PD Clinical Trial	Lu AF82422, a human monoclonal antibody against α -synuclein for the treatment of α -synucleinopathies, selected based on epitope and potency in α -synuclein seeding models	Pekka Kallunki H. Lundbeck, Denmark
Clinical Trial	How a diabetes drug may hold promise for early Alzheimer's: Insights from the EVOKE trials	Sebastian Meyhöfer Novo Nordisk, Germany
PD Clinical Trial	Safety, tolerability and pharmacokinetics in healthy volunteers after administration of exidavnemab, a high affinity and high selectivity antibody targeting toxic aggregates of α -synuclein	Emma Boström Bioartcic, Sweden
Panel Q&A of Session Speakers <i>Chair: Oliver Peters, Psychiatric Clinic Frankfurt Oder, Germany</i>		
14:30		
Coffee Break & Final Poster Session		
15:30		
Panel Discussion:		
<ul style="list-style-type: none">• How much more evidence do we need before the prion-like disease mechanism is finally generally accepted and communicated?• Prevention and treatment of neurodegeneration: Finally, selected Aβ-antibodies work, but which possible modes of action offer more affordable therapy against a prion-like disease mechanism in the future?• What influence does life style and BMI really have on neurodegenerative disease progression?		
Panel Participants:		
Oliver Peters	Clinic for Psychiatry and Psychotherapy, Frankfurt Oder, Germany	
Sebastian Meyhöfer	Novo Nordisk, Germany	
Neil Cashman	ProMIS, Vancouver, Canada	
Moderator: Andreas Köpke, bioExpert		
16:15		
Price for the Best Poster <i>'Scientific progress towards improving the life of patients and their families' presented at the International Neuro4D Conference 2024</i>		
16:25		
Summary and wrap-up of the conference		
16:30		
END OF THE CONFERENCE AND DEPARTURE		